ATS Corporation Conference Call Summary Company Overview - **Company**: ATS Corporation (NYSE: ATS) - **Date**: November 18, 2025 - **Speaker**: Ryan McLeod, Interim CEO Key Points Industry and Market Dynamics - **Life Sciences Sector**: ATS has six independent life science businesses, with a focus on automation and drug delivery mechanisms, particularly auto injectors, which account for approximately 10% of total revenues and 20% of life science revenues [7][15][16] - **Growth in GLP-1 Market**: The GLP-1 segment is expected to remain a significant revenue contributor over the next five years, with high growth potential due to increasing consumer demand for drug delivery devices [15][23] - **Radiopharma Growth**: Investment in radiopharmaceuticals for cancer treatment is driving growth, with a shift towards personalized medicine leading to more specific therapies [17][18] - **Wearable Devices**: ATS is involved in the development of wearable devices, expanding their market from diabetes treatment to general consumer applications [19][20] Financial Performance - **Q2 Fiscal Results**: Revenues increased by approximately 12% year-over-year, with a backlog growth of 13.5% [11][12] - **Margin Expansion**: ATS is on track for high single-digit organic growth and has seen sequential margin expansion, particularly in Q2 [12][13] - **Transportation Segment**: The transportation business has stabilized at around $50 million per quarter, with no expected growth in the next three to five years due to market saturation and technology changes [30][31] Strategic Initiatives - **Restructuring and Optimization**: ATS has undergone significant restructuring to optimize performance, particularly in the transportation segment, while exploring adjacent opportunities in industrial manufacturing and reshoring [31][33] - **Nuclear Business Growth**: The nuclear segment is expected to grow, with a focus on refurbishment, decommissioning, and new builds, particularly in the context of increasing energy demands [25][27][28] Leadership Transition - **CEO Search**: The board is actively engaged in the search for a new CEO, prioritizing candidates with strong backgrounds in continuous improvement and M&A [56][59] Other Considerations - **Working Capital Management**: ATS aims to reduce working capital investment from approximately 18% to a target of 15% of sales, with larger life science programs expected to contribute to this goal [46][48] - **Market Positioning**: ATS is focused on high-consequence markets such as life sciences and food, which are less cyclical and emphasize quality and time to market [44][45] This summary encapsulates the key insights from the ATS Corporation conference call, highlighting the company's strategic focus, market dynamics, and financial performance.

Group 1: Partnership Overview - Samsung C&T and Siemens have initiated a collaboration focusing on next-generation infrastructure projects in Saudi Arabia, Canada, and Thailand, covering sectors such as airports, hospitals, data centers, and buildings [1] - The partnership aims to leverage Siemens' Smart Infrastructure and Digital Industries portfolio, including technologies like Building X, Electrification X, and Industrial Metaverse applications, to enhance design, efficiency, and performance [1] Group 2: Company Profiles - Siemens Smart Infrastructure addresses urbanization and climate change challenges by connecting energy systems, buildings, and industries, providing a comprehensive end-to-end portfolio from power generation to consumption [2] - Siemens generated revenue of €78.9 billion and net income of €10.4 billion in fiscal 2025, employing around 318,000 people globally [2] - Samsung C&T is recognized for its engineering, procurement, and construction expertise, with landmark projects including the Burj Khalifa and the Riyadh Metro, and is focusing on eco-friendly energy solutions and AI-related infrastructures for future growth [2]

Siemens has announced plans to ‘deconsolidate’ its remaining stake in Siemens Healthineers by transferring 30% of shares to Siemens shareholders. Siemens, whose stake had stood at 67%, will hand the shares over via a direct spin-off as ‘preferable option’. Deciding to deconsolidate the Healthineers business follows a thorough assessment and strategic review of how both companies can best realise their full potential, accelerate their respective transformations, and successfully tap into new areas of grow ...

Siemens Healthineers Capital Markets Day Summary Company Overview - **Company**: Siemens Healthineers (OTCPK: SEMH.F) - **Event**: 2025 Capital Markets Day - **Date**: November 17, 2025 Key Points Industry Position and Strategy - Siemens Healthineers is recognized as a leader in the healthcare industry, particularly in imaging and precision therapies, with a strong presence in the Americas, Europe, China, and APJ regions [6][9][10] - The company operates in 70 countries and has an installed base of 700,000 systems, impacting 3 billion patients annually [6][7] - The focus is on elevating health globally, addressing non-communicable diseases (NCDs) which account for 75% of global deaths [17][18] Financial Performance - Revenue growth has averaged over 6% per year since the last capital market day, with EPS growth at 11% per year [10][58] - Siemens Healthineers reported revenues of over EUR 23 billion and EBIT close to EUR 4 billion [9] - The company has a backlog of over EUR 6 billion from value partnerships [8][12] Research and Development - Siemens Healthineers invests more than EUR 2 billion annually in R&D, with a focus on software, AI, and data science [7] - The company holds 1,300 patent families in healthcare AI, showcasing its commitment to innovation [7] Business Segments - The company operates in three synergistic business segments: Imaging, Varian (Precision Therapy), and Advanced Therapies, with Diagnostics following a separate path [9][13] - Diagnostics has improved margins by 8 percentage points since 2023 and is expected to have more entrepreneurial freedom for strategic growth [13] Future Growth and Targets - Midterm growth targets (2027-2030) include revenue growth of 5-9% and double-digit EPS growth [41][42] - The company aims for margin expansion of about 100 basis points per year in Precision Therapy and mid-single-digit growth in Diagnostics [42] - Sustainability targets include reducing carbon footprint by 90% in scope one and two by 2030 [42] Customer Challenges - Key challenges for customers include efficiency, clinical excellence, and access to care, driven by staff shortages and the need for improved healthcare systems [34][35][36] - Siemens Healthineers aims to address these challenges through value partnerships and innovative solutions [37][38] Technological Innovations - The company is focusing on personalized treatment approaches for NCDs, leveraging AI and advanced imaging technologies [22][23][24] - Innovations such as photon counting CT and AI-enabled MRI are positioned to enhance early detection and treatment planning [25][29] Capital Allocation and Financial Strategy - Siemens Healthineers has a stable dividend policy, proposing EUR 1.00 per share for the next AGM, with a commitment to maintain a progressive dividend [52] - The company targets a net debt to EBITDA ratio of 2.5 over the next two years, aiming for a strong investment-grade rating [54] Conclusion - Siemens Healthineers is well-positioned to tackle significant healthcare challenges through its innovative technologies, strong market presence, and strategic focus on growth and sustainability [39][40]

Capital Markets Day London, November 17, 2025 Unrestricted © Siemens Healthineers, 2025 1 Unrestricted © Siemens Healthineers, 2025 Capital Markets Day 2025 Safe Harbor Statement This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the in ...

Siemens Healthineers is studying options for its Diagnostics business that could include a future sale, a few days after former parent Siemens said it plans to reduce its majority holding in the maker of MRI scanners https://t.co/YPUyr81Hg6 ...

In an inflated market, like the one I believe we currently have, finding value or undervaluation is never the easiest thing. I would go so far as to say it becomes almost impossible after a while, not because some companiesWolf Report is a senior analyst and private portfolio manager with over 10 years of generating value ideas in European and North American markets. He is a contributing author and analyst for the investing group iREIT®+HOYA Capital and Wide Moat Research LLC where in addition to the U.S. m ...

Core Insights - The current market is perceived as inflated, making it challenging to identify undervalued stocks [1] - The analyst has over 10 years of experience in generating value ideas in European and North American markets [1] Company and Market Analysis - The analyst covers a wide range of markets including Scandinavia, Germany, France, the UK, Italy, Spain, Portugal, and Eastern Europe [1] - The focus is on finding reasonably valued stock ideas within these markets [1]

Core Viewpoint - Siemens will transfer 30% of its shares in Siemens Healthineers to its shareholders, relinquishing its controlling stake in the imaging and diagnostics company [1][2]. Group 1: Strategic Implications - Siemens currently holds a 67% stake in Siemens Healthineers and aims to focus on its core technology portfolio with increased capital allocation flexibility, which is expected to accelerate growth [2]. - The decision is seen as a natural progression towards Siemens Healthineers becoming a fully independent company, following its initial public offering in 2018 [3]. - Both companies will benefit from enhanced strategic flexibility, allowing for tailored capital allocation to accelerate value creation in their respective markets [4]. Group 2: Financial Performance - Siemens Healthineers reported a 4% year-over-year decline in fourth-quarter net income, with revenue remaining roughly flat, indicating a challenging environment influenced by higher tariffs [5]. Group 3: Transaction Details - Further details regarding the structure and timing of the share transfer will be disclosed in early Q2 2026, pending regulatory reviews and approvals from shareholder meetings of both companies [5].

By John Revill ZURICH (Reuters) -Siemens' shares fell almost 6% on Thursday as a hike in its medium-term sales growth forecast failed to allay investors amid profit-taking and disappointment ​about next year's profit outlook. The company, which on Wednesday said it plans to eventually cut its stake ‌in Siemens Healthineers to 20%, said it expects its sales to rise by 6-8% next year and 6-9% in the ‌mid term. Both figures would mark an acceleration from the 5% revenue growth rate Siemens reported on Thur ...